Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | NR4A2 | P43354 | 8/20 | 0.59 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.59 |
| ▸ | FOS | P01100 | 1/20 | 0.57 |
| ▸ | JUN | P05412 | 1/20 | 0.57 |
| ▸ | FABP1 | P07148 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.54 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16108766 | 0.88 | NR1H4 (0.60) | NR1H4KMT2AKAT6AFOSJUN | |
| SCHEMBL1436279 | 0.87 | NR1H4 (0.63) | NR1H4KMT2AKAT6AFOSJUN | |
| SCHEMBL31490934 | 0.86 | KMT2A (0.59) | NR1H4KMT2ANR4A2AKR1C3NR4A1 | |
| SCHEMBL14897011 | 0.86 | KMT2A (0.59) | NR1H4KMT2ANR4A2AKR1C3NR4A1 | |
| SCHEMBL3248766 | 0.85 | NR1H4 (0.58) | NR1H4KMT2AKAT6AFOSJUN | |
| SCHEMBL7260601 | 0.85 | PARP1 (0.60) | NR1H4KMT2AKAT6AFOSJUN | |
| SCHEMBL23983129 | 0.85 | NR1H4 (0.58) | NR1H4KMT2ANR4A2KAT6AAKR1C3 | |
| SCHEMBL9741522 | 0.85 | NR4A2 (0.61) | NR1H4KMT2ANR4A2AKR1C3NR4A1 | |
| SCHEMBL19019858 | 0.84 | NR1H4 (0.76) | NR1H4KMT2ANR4A2AKR1C3NR4A1 | |
| SCHEMBL26049008 | 0.84 | NR1H4 (0.60) | NR1H4KMT2AKAT6AFOSJUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| EP-2807162-B1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-06-07 | — | — | EP | disclosed |
| CN-104411707-B | Substituted phenylimidazopyrazoles and their use | 拜耳药业股份公司 | 2017-03-01 | — | — | CN | disclosed |
| US-9394309-B2 | Substituted phenylimidazopyrazoles and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-19 | — | — | US | disclosed |
| EP-2791130-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLU5 RECEPTORS | BOEHRINGER INGELHEIM INT (DE) | 2016-03-16 | — | — | EP | disclosed |
| CN-104411707-A | Substituted phenylimidazopyrazoles and their use | Bayer Pharma AG | 2015-03-11 | — | — | CN | disclosed |
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-01 | — | — | US | disclosed |
| EP-2807162-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2014-12-03 | — | — | EP | disclosed |
| EP-2136624-A1 | ALLYLQXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS | Emisphere Technologies, Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| EP-1831198-B1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008116141-A1 | ALLYLQXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008116141-A1 | ALLYLQXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| CN-101128454-A | Pyridine carboxamide derivatives for use as anticancer agents | ASTRAZENECA AB (SE) | 2008-02-20 | — | — | CN | disclosed |
| CN-101080396-A | Quinoxalines as B Raf inhibitors | ASTRAZENECA AB (SE) | 2007-11-28 | — | — | CN | disclosed |
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | VHL, FLT4, FLT1 | NR1H4 2915/4885KMT2A 3556/4885NR4A2 878/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | NR1H4 2049/4885KMT2A 4371/4885NR4A2 2675/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | NR1H4 2049/4885KMT2A 4371/4885NR4A2 2675/4885 |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | NR1H4 42/4885KMT2A 2770/4885NR4A2 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.